HIGH GRADE GLIOMAS

This study is for children and teens (ages 3 to 18) with certain solid tumors that have returned or not responded to standard treatment. The tumors must have a specific marker called SSTR. The study combines two drugs: Lutathera (a radioactive drug that targets SSTR) and Olaparib…

This early-phase trial tests a new treatment for adults with recurrent glioblastoma, an aggressive brain cancer. The treatment uses specially engineered immune cells (CAR-NK cells) designed to recognize and attack tumor cells. Up to 36 participants will receive the cells directly…

This early-phase trial is testing a combination of three treatments for children whose brain tumors have come back or not responded to standard care. The experimental drug SGT-53 delivers a normal TP53 gene to tumor cells, and is given alongside the immunotherapy Nivolumab and ra…

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack…

This early-phase trial tests a special version of the immunotherapy drug nivolumab that has a fluorescent dye attached (nivo800). The dye makes the drug glow under near-infrared light, allowing researchers to see exactly where the drug goes in the tumor during surgery. About 38 a…